Le Lézard
Classified in: Health, Business

HLS Therapeutics Inc. Opens the Market


TORONTO, March 20, 2019 /CNW/ - William Wells, Executive Chairman, alongside Greg Gubitz, CEO, HLS Therapeutics Inc. (HLS), joined joined Dani Lipkin, Innovation Sector Head, Capital Formation, Toronto Stock Exchange and TSX Venture Exchange, to open the market. Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS Therapeutics Inc. graduated and commenced trading on Toronto Stock Exchange on February 7, 2019.

SOURCE TMX Group Limited


These press releases may also interest you

at 06:00
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin's Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...

at 06:00
65,000 ONTARIO HOSPITAL WORKERS AWARDED 6% WAGE INCREASE, BENEFIT IMPROVEMENTS IN NEW CONTRACT
65,000 Ontario hospital workers represented by the Ontario Council of Hospital Unions-CUPE (OCHU-CUPE) and SEIU Healthcare will see a 6% wage increase (3% wage increases in each of the next two years), improvements to health and dental benefits,...

at 05:29
SmartCella strengthens team with Dr Ricardo Baptista as CTO
SmartCella Holding AB today announces that Dr Ricardo Baptista has been appointed Chief Technology Officer (CTO) and Head of Procella. Ricardo is an experienced Biochemical Engineer with almost 20-years of global experience in the medical...

at 05:15
Employment and Education: Striking Disparities for Young People in Quebec's Youth Protection System
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech Announces Oral Presentation on ATX-01 at the Oligonucleotide & Peptide Therapeutics (TIDES) Conference 2024
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
IDTechEx Examines the Opportunities for Wearables in Digital Health
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

More news about Health...


News published on and distributed by: